Temocapril (hydrochloride)

Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases^[1][2]. IC50 & Target: ACE^[1] In Vitro: Temocapril hydrochloride is a prodrug of the ACE inhibitor, Temocaprilat. Temocapril hydrochloride can be readily uptaken via the small intestine, and then be converted to its active metabolite (temocaprilat) by CES1 (human carboxylesterase 1) in the liver^[1].
Temocapril hydrochloride (500 nM) reduces the inhibitory effects of RS (N-acetyltetradecapeptide renin substrate) and AngI on neurogenic vasodilation in the SHR^[2].
Temocapril hydrochloride (0.1-10 μM; 24 h) shows inductive effects on redox proteins TRX while no effect on antioxidant enzymes Cu/ZnSOD and Mn-SOD expressions^[3].
In Vivo: Temocapril hydrochloride (10 mg/kg; p.o.; 21 d) enhances cardiomyocyte thioredoxin expression and ameliorates autoimmune myocarditis^[3].
Temocapril hydrochloride (30 mg/kg; p.o.; daily; for 4 weeks) suppresses Angiotensin I-induced hypertension, plasma and renal ACE activity, but fails to reduce the level of Ang II in the kidney^[4].